-
1 Comment
Rua Life Sciences Plc is currently in a long term uptrend where the price is trading 39.4% above its 200 day moving average.
From a valuation standpoint, the stock is 90.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 41.3.
Based on the above factors, Rua Life Sciences Plc gets an overall score of 2/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
Exchange | LSE |
CurrencyCode | GBP |
ISIN | GB0033360586 |
Dividend Yield | 0.0% |
---|---|
Target Price | 400 |
Market Cap | 20M |
PE Ratio | None |
Beta | 1.28 |
Rua Life Sciences Plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in the United Kingdom. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as Reaction Injection Molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to Rua Life Sciences Plc in June 2020. Rua Life Sciences Plc was incorporated in 1996 and is based in Glasgow, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AOR.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025